ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1241

Beyond Pain Severity in Psoriatic Arthritis: Pain Catastrophizing Independently Impacts Disease Burden and Quality of Life

Kyra Chen1, Uma Scher2 and Rebecca Haberman3, 1NYU Grossman School of Medicine and NYU Langone Health Psoriatic Arthritis Center, New York, 2NYU School of Medicine, Scarsdale, NY, 3NYU Langone Health, New York, NY

Meeting: ACR Convergence 2025

Keywords: mental health, pain, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Pain remains a major burden in psoriatic arthritis (PsA), often persisting despite effective control of synovial inflammation. This persistent pain may prevent patients from achieving remission or meaningful improvements in quality of life (QoL). Although pain severity is typically emphasized in clinical evaluation, emerging evidence suggests that psychological contributors—particularly maladaptive cognitive-emotional processes such as pain catastrophizing—may play a critical, underrecognized role. Pain catastrophizing, defined by magnification of symptoms, ruminative thoughts, and a sense of helplessness, is well documented in other chronic pain conditions but remains poorly characterized in PsA. In this study, we assess the prevalence and impact of pain catastrophizing in a real-world PsA population at the NYU Psoriatic Arthritis Center (PAC).

Methods: Consecutive patients meeting CASPAR criteria were enrolled at the NYU PAC into a cross-sectional study of pain and psychosocial features. Participants completed the Pain Catastrophizing Scale (PCS), which includes three subscores (helplessness, magnification, rumination); a total score >30 was considered clinically significant. Depression was defined by PHQ-9 ≥10. Pain severity was rated on a 0–10 scale. Outcomes included Minimal Disease Activity (MDA), low disease activity per cDAPSA (≤13), and multiple QoL indices (EQ-5D, PROMIS-29). Associations between PCS and disease outcomes were assessed via logistic and linear regression, adjusting for pain intensity, depression, and sex.

Results: Among 91 PsA patients, 5 (5.5%) patients met criteria for clinically significant (PCS >30), all of whom were women. Subscale symptom prevalence included helplessness (6), magnification (12), and rumination (3). Higher PCS scores were associated with reduced odds of achieving cDAPSA low disease activity (OR 0.95, 95%CI 0.90–0.99, p=0.022), and a trend toward lower MDA rates (OR 0.95, CI 0.91–1.00, p=0.060). Catastrophizing was associated with poorer QoL (EQ-5D index b=-0.009 95%CI -0.013, -0.006, p < 0.001), with helplessness driving the strongest effect (β = –0.023, 95%CI –0.03 to –0.02, p < 0.001). After adjusting for current pain level, sex, and the presence of active depression, PCS remained independently associated with QoL (b= -0.004, 95%CI -0.01, -0.004, p =0.03), greater pain interference (β = 0.230, 95%CI 0.090–0.370, p=0.002), and reduced participation in social roles (β = –0.338, 95%CI –0.52 to –0.156, p < 0.001). No association was found with physical function (b= -0.91, 95%CI -0.256, -0.074, p =0.276).

Conclusion: Our findings highlight the critical role of psychological pain processing in PsA. Pain catastrophizing—often undetected by standard clinical assessments—exerts a substantial and independent effect on patient-reported outcomes, even after accounting for actual pain intensity and depression. Addressing this process through interventions such as cognitive behavioral therapy or integrative psychosocial support may be necessary to improve holistic disease management and help patients achieve true remission and restoration of function.


Disclosures: K. Chen: None; U. Scher: None; R. Haberman: Johnson and Johnson, 1, 5, Novartis, 1.

To cite this abstract in AMA style:

Chen K, Scher U, Haberman R. Beyond Pain Severity in Psoriatic Arthritis: Pain Catastrophizing Independently Impacts Disease Burden and Quality of Life [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/beyond-pain-severity-in-psoriatic-arthritis-pain-catastrophizing-independently-impacts-disease-burden-and-quality-of-life/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/beyond-pain-severity-in-psoriatic-arthritis-pain-catastrophizing-independently-impacts-disease-burden-and-quality-of-life/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology